Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the initiation of the first of two Phase 3 clinical trials to assess myocardial perfusion using Positron Emission Tomography (PET) imaging with flurpiridaz F 18 in patients with suspected or known coronary artery disease (CAD). The study will evaluate the diagnostic efficacy of flurpiridaz F 18 PET myocardial perfusion imaging (MPI), compared with single photon emission computed tomography (SPECT) MPI in the detection of significant coronary artery disease. The Phase 3 clinical development program will include two open-label trials in approximately 1,350 patients at approximately 100 clinical trial sites worldwide, including locations in the U.S., Canada, Europe and South America.
“SPECT imaging has a number of challenges, including sub-optimal image quality, underestimation of ischemia, low sensitivity for multi-vessel CAD, and artifacts that result in false positive test results”
"The initiation of the first Phase 3 trial with flurpiridaz F 18 marks a critical step in the development of this novel imaging agent and exemplifies our commitment to develop next generation diagnostic imaging products," said Don Kiepert, President and Chief Executive Officer of Lantheus Medical Imaging. "There is a significant need for improved non-invasive imaging tools to help physicians better evaluate and manage patients with cardiovascular disease. Clinical trial results to date show that PET with flurpiridaz F 18 can improve diagnostic performance compared to SPECT and we anticipate that the results from our Phase 3 clinical program will confirm the findings seen in previous studies, reinforcing the diagnostic efficacy of PET imaging for evaluating coronary artery disease."
The first Phase 3 clinical trial is an open-label, international multicenter study of flurpiridaz F 18 injection for PET MPI compared to SPECT MPI in patients with suspected or known CAD referred for invasive coronary angiography (ICA). The trial will enroll approximately 680 patients. The primary objective of the study is to assess the diagnostic efficacy (sensitivity and specificity) of flurpiridaz F 18 PET MPI compared to SPECT MPI in the detection of significant CAD as defined by ICA or a documented history of myocardial infarction. Secondary endpoints include the localization of significant CAD, identification of multi-vessel CAD, and the evaluation of image quality, diagnostic certainty, and reversible defect size with flurpiridaz F 18 PET MPI compared to SPECT MPI. Three independent, blinded readers will assess the PET rest and stress images as well as the SPECT rest and stress images for each patient.
"SPECT imaging has a number of challenges, including sub-optimal image quality, underestimation of ischemia, low sensitivity for multi-vessel CAD, and artifacts that result in false positive test results," said Jamshid Maddahi, M.D., F.A.C.C., Professor of Molecular and Medical Pharmacology (Nuclear Medicine) and Medicine (cardiology) at the David Geffen School of Medicine at UCLA, lead investigator of the study. "PET MPI has the potential to reduce the number of patients sent to cardiac catheterization unnecessarily, improve the identification of patients with risky multi-vessel disease, and reduce redundant downstream testing due to non-definitive results."
Lantheus presented Phase 2 study results for flurpiridaz F 18 at the International Conference on Nuclear Cardiology and Cardiac CT (ICNC10) in May in Amsterdam and at the SNM (Society of Nuclear Medicine) 58th Annual Meeting in June in San Antonio. The findings demonstrated PET myocardial perfusion imaging with flurpiridaz F 18 provided superior image quality, diagnostic certainty, and diagnostic performance for detecting CAD compared to SPECT MPI, the current standard for the non-invasive detection of CAD. The data also demonstrated a strong safety profile for PET imaging with flurpiridaz F 18.
"We are pleased to announce the initiation of the Phase 3 trial with flurpiridaz F 18, which follows on the heels of our Phase 2 data presented at ICNC10 and SNM," said Dana S. Washburn, M.D., Vice President, Clinical Development and Medical Affairs at Lantheus Medical Imaging. "The results to date with flurpiridaz F 18 suggest that this agent demonstrates improved image quality compared to SPECT and a may offer a more thorough evaluation of coronary atherosclerosis and resulting blood flow abnormalities. We believe the Phase 3 study will continue to demonstrate the strong clinical benefits of cardiac PET imaging with flurpiridaz F 18 compared to SPECT."
The Phase 3 clinical program has received a Special Protocol Assessment from the U.S. Food and Drug Administration.
Lantheus Medical Imaging, Inc.